Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:002907)
13.93
+0.03 (0.22%)
Apr 29, 2026, 3:04 PM CST
SHE:002907 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 274.34 | 456.55 | 437.56 | 503.53 | 429.97 |
Short-Term Investments | - | 30.35 | 50 | - | - |
Trading Asset Securities | 351.22 | 120.61 | - | - | 80.61 |
Cash & Short-Term Investments | 625.55 | 607.51 | 487.56 | 503.53 | 510.58 |
Cash Growth | 2.97% | 24.60% | -3.17% | -1.38% | -3.93% |
Accounts Receivable | 287.5 | 272.7 | 245.46 | 315.03 | 238.5 |
Other Receivables | 3.87 | 3.06 | 4.24 | 9.6 | 4.33 |
Receivables | 291.37 | 275.76 | 249.71 | 324.63 | 242.83 |
Inventory | 139.03 | 140.13 | 151.68 | 114.76 | 127.44 |
Other Current Assets | 72.9 | 7.95 | 5.69 | 14.03 | 13.25 |
Total Current Assets | 1,129 | 1,031 | 894.64 | 956.95 | 894.1 |
Property, Plant & Equipment | 492.68 | 537.74 | 593.41 | 621.94 | 654.21 |
Long-Term Investments | 72.41 | 93.65 | 98.39 | 84.48 | 57.05 |
Other Intangible Assets | 209.39 | 125.89 | 107.14 | 75.26 | 76.79 |
Long-Term Deferred Tax Assets | 19.72 | 17.26 | 15.69 | 18.66 | 16.96 |
Long-Term Deferred Charges | 33.04 | 36.97 | 60.96 | 44.01 | 24.89 |
Other Long-Term Assets | 71.07 | 74.7 | 81.23 | 65.37 | 47.48 |
Total Assets | 2,027 | 1,918 | 1,851 | 1,867 | 1,771 |
Accounts Payable | 69.56 | 64.36 | 55.23 | 48.04 | 76.1 |
Accrued Expenses | 27.83 | 32.3 | 29.44 | 40.29 | 26.94 |
Current Portion of Long-Term Debt | 38.79 | - | - | - | - |
Current Portion of Leases | - | 0.09 | 0.14 | 0.11 | 0.13 |
Current Income Taxes Payable | 13.49 | 4.62 | 0.76 | 1.97 | 0.18 |
Current Unearned Revenue | 10.06 | 9.74 | 5.69 | 6.73 | 4.35 |
Other Current Liabilities | 104.72 | 100.93 | 97.41 | 114.18 | 99.27 |
Total Current Liabilities | 264.44 | 212.03 | 188.68 | 211.32 | 206.97 |
Long-Term Debt | - | - | - | - | 250.92 |
Long-Term Leases | 3 | 0.04 | 0.14 | 0.06 | 0.08 |
Long-Term Unearned Revenue | 37.55 | 42.99 | 43.03 | 43.59 | 46.33 |
Long-Term Deferred Tax Liabilities | 14.98 | 2.48 | 1.68 | 1.3 | 1.27 |
Total Liabilities | 319.97 | 257.55 | 233.53 | 256.28 | 505.56 |
Common Stock | 417.6 | 417.6 | 417.6 | 417.6 | 401.69 |
Additional Paid-In Capital | 461.46 | 459.33 | 458.73 | 454.72 | 129.12 |
Retained Earnings | 812.48 | 782.89 | 741.66 | 738.19 | 659.79 |
Treasury Stock | - | - | - | - | -6.55 |
Comprehensive Income & Other | -0.22 | 0.18 | -0.07 | -0.11 | 81.87 |
Total Common Equity | 1,691 | 1,660 | 1,618 | 1,610 | 1,266 |
Minority Interest | 15.87 | - | - | - | - |
Shareholders' Equity | 1,707 | 1,660 | 1,618 | 1,610 | 1,266 |
Total Liabilities & Equity | 2,027 | 1,918 | 1,851 | 1,867 | 1,771 |
Total Debt | 41.79 | 0.13 | 0.28 | 0.17 | 251.12 |
Net Cash (Debt) | 583.76 | 607.39 | 487.28 | 503.36 | 259.45 |
Net Cash Growth | -3.89% | 24.65% | -3.19% | 94.01% | -8.68% |
Net Cash Per Share | 1.40 | 1.45 | 1.17 | 1.25 | 0.65 |
Filing Date Shares Outstanding | 417.13 | 417.6 | 417.6 | 417.6 | 401.71 |
Total Common Shares Outstanding | 417.13 | 417.6 | 417.6 | 417.6 | 401.69 |
Working Capital | 864.4 | 819.31 | 705.96 | 745.63 | 687.13 |
Book Value Per Share | 4.05 | 3.98 | 3.87 | 3.86 | 3.15 |
Tangible Book Value | 1,482 | 1,534 | 1,511 | 1,535 | 1,189 |
Tangible Book Value Per Share | 3.55 | 3.67 | 3.62 | 3.68 | 2.96 |
Buildings | - | 310.3 | 310.25 | 297.72 | 292.53 |
Machinery | - | 598.97 | 582.48 | 566.85 | 536.22 |
Construction In Progress | - | 10.19 | 25.78 | 17.52 | 23.55 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.